High-dose cholecalciferol supplementation for vitamin D deficiency in haemodialysis patients

Journal of International Medical Research

Volumn 39, Issue 3, 2011, Pages 1099-1106

  Jakopin, E ^a   Pecovnik Balon, B ^a,b   Ekart, R ^a,b   Gorenjak, M ^a,b  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^b UNIVERSITY OF MARIBOR   (Slovenia)

Author keywords

25 hydroxyvitamin D; Cholecalciferol; Haemodialysis patients; High dose vitamin D supplementation; Vitamin D deficiency; Vitamin D insufficiency

Indexed keywords

25 HYDROXYVITAMIN D; COLECALCIFEROL; PLIVIT D3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 80052218258     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900345     Document Type: Article

References (25)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-S130.
2. London GM, Guérin AP, Verbeke FH, et al: Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620.
3. Pecovnik-Balon B, Jakopin E, Bevc S, et al: Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients. Ther Apher Dial 2009; 13: 268-272.
4. Wolf M, Shah A, Gutierrez O, et al: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013.
5. 3. Semin Dial 2007; 20: 316-324.
6. Holick MF: Sunlight and vitamin D for bone health and prevention of autoimmune disease, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80(6 suppl): 1678S-1688S.
7. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 suppl 3): S1-S201.
8. Hsia J, Heiss G, Ren H, et al: Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115: 846-854.
9. Saab G, Young DO, Gincherman Y, et al: Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105: c132-c138.
10. Tokmak F, Quack I, Schieren G, et al: High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 4016-4020.
11. Jean G, Souberbielle JC, Chazot C: Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 2009; 24: 3799-3805.
12. Jean G, Terrat JC, Vanel T, et al: Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 2008; 23: 3670-3676.
13. Al-Aly Z, Qazi RA, González EA, et al: Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007; 50: 59-68.
14. Maheut H, Chevriot F, Marty H, et al: Why and how correct calcidiol deficiency in haemodialysis patients? Nephrol Ther 2009; 5: 542-549 [in French, English abstract].
15. Jean G, Chazot C: The French clinician's guide to the kidney disease: improving global outcomes (KDIGO) for chronic kidney disease-mineral and bone disorders (CKD-MBD). Nephrol Ther 2010; 6: 151-157 [in French, English abstract].
16. 3 in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol 2006; 38: 323-329.
17. Gonzáles EA, Sachdeva A, Oliver DA, et al: Vitamin D insufficiency and deficiency in chronic kidney disease. Am J Nephrol 2004; 24: 503-510.
18. Cigolini M, Iagulli MP, Miconi V, et al: Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 2006; 29: 722-724.
19. Zitterman A, Schleithoff SS, Tenderich G, et al: Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003; 41: 105-112.
20. Scragg R, Jackson R, Holdaway IM, et al: Myocardial infarction is inversly associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol 1990; 19: 559-563.
21. Wang TJ, Pencina MJ, Booth SL, et al: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-511.
22. 3 in humans. J Clin Endocrinol Metab 2004; 89: 5387-5391.
23. 2. Am J Clin Nutr 1998; 68: 854-858.
24. Nilsson SF, Ostberg L, Peterson PA: Binding of vitamin D to its human carrier plasma protein. Biochem Biophys Res Commun 1972; 46: 1380-1387.
25. Mistretta VI, Delanaye P, Chapelle JP, et al: Vitamin D2 or vitamin D3? Rev Med Interne 2008; 29: 815-820 [in French, English abstract].